Sustainability report

Healthcare process innovation

Edwards Lifesciences’ work to support healthcare process innovation supports our aspiration of Transforming Patient Lives with Breakthrough Medical Technologies, as well as enhancing a value-based healthcare system.

Definition

Developing innovations that allow Edwards’ products to improve efficiency, safety, and effectiveness of healthcare processes.

Our aspirations

icon-aspirations-transform

Transforming patient lives with breakthrough medical technologies

Material topics
Highlight story

SAPIEN 3 transcatheter valve demonstrates significant cost savings over surgery in intermediate risk patients

At the 29th Transcatheter Cardiovascular Therapeutics annual scientific symposium in Denver, new data demonstrated substantial economic advantages of the Edwards SAPIEN 3 transcatheter aortic heart valve for patients suffering from severe, symptomatic aortic stenosis who are at intermediate risk for open-heart surgery. The economic analysis of the SAPIEN 3 valve compared to surgery involved more than 2,000 patients enrolled in both the PARTNER II A trial and the SAPIEN 3 intermediate risk trial. "Based on both clinical and economic considerations, these findings demonstrate that TAVR should be the preferred strategy for patients with severe aortic stenosis at intermediate surgical risk," said David J. Cohen, M.D., Professor of Medicine at the University of Missouri-Kansas City and Director of Cardiovascular Research at Saint Luke's Mid America Heart Institute. Transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 valve added 0.27 quality-adjusted life years (QALY) per patient at a lifetime cost savings of approximately $10,000 compared with surgery. Reduced length of stay, simpler, more efficient procedures, fewer repeat hospitalizations, and less time in rehabilitation contributed to the economically dominant results of the SAPIEN 3 valve